VivoSeq
Oncology

Gastrointestinal Tumors

0

Pipeline Programs

10

Active Trials

6

Companies Involved

Gastrointestinal Tumors is an early-stage landscape with 0 programs across 6 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., Pfizer, Shanghai Juncell Therapeutics.

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

15/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

26

clinical trials

Unknown status8 · 31%
Recruiting7 · 27%
Completed4 · 15%
Terminated3 · 12%
Not yet recruiting2 · 8%
Active, not recruiting1 · 4%
Other1 · 4%

Trial Activity

26 trials

A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
Not yet recruiting·DDualityBio Inc.·Phase 1/2·NCT07263594·127 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)